EBOS Group Ltd (EBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH10654D
- Pages: 27
- November 2018
- Total Views:1154
- Region : Asia
- GlobalData
- Equity Research Report

Details
Summary
EBOS Group Ltd (EBOS) is a healthcare products supplier that markets, sells and distributes healthcare, medical and pharmaceutical products. It also markets and distributes animal care products and offers distribution, warehousing and logistics support to pharmaceutical manufacturers and medical device suppliers. The company offers products under various brands such as Symbion, Pro Pharma, Minfosa, Master Pet, Vita Pet, Black Hawk and Faulding among others. EBOS serves private and public hospitals, general practitioners, aged care facilities, community centers, pharmacies, professionals, consumers, pet stores, veterinary clinics and manufacturers. It has operational presence in Australia and New Zealand. EBOS is headquartered in Docklands, Victoria, Australia.
EBOS Group Ltd (EBO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
EBOS Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
EBOS Group Ltd, Medical Devices Deals, 2012 to YTD 2018 9
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
EBOS Completes Private Placement Of Shares For USD 73 Million 11
EBOS Announces Rights Issue Of Shares For USD 121 Million 12
Acquisition 13
Ebos Group Receives Shareholders' Approval To Acquire Symbion From Zuellig Group For USD 886 Million 13
EBOS Group Ltd-Key Competitors 15
EBOS Group Ltd-Key Employees 16
EBOS Group Ltd-Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 19
Financial Announcements 19
Aug 23, 2018: EBOS delivers record 2018 earnings 19
Feb 21, 2018: EBOS delivers record first-half earnings 20
Aug 24, 2017: EBOS reports record earnings for 2017 22
Feb 22, 2017: EBOS Group Announces Strong first half delivers double-digit revenue and profit growth 24
Corporate Communications 26
Dec 13, 2017: EBOS Group announces its next CEO 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27
List Of Figure
List of Figures
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
EBOS Group Ltd, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
EBOS Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
EBOS Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
EBOS Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
EBOS Group Ltd, Medical Devices Deals, 2012 to YTD 2018 9
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
EBOS Completes Private Placement Of Shares For USD 73 Million 11
EBOS Announces Rights Issue Of Shares For USD 121 Million 12
Ebos Group Receives Shareholders' Approval To Acquire Symbion From Zuellig Group For USD 886 Million 13
EBOS Group Ltd, Key Competitors 15
EBOS Group Ltd, Key Employees 16
EBOS Group Ltd, Other Locations 17
EBOS Group Ltd, Subsidiaries 17
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
EBOS Group Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
EBOS Group Ltd (EBOS) is a healthcare products supplier that markets, sells and distributes healthcare, medical and pharmaceutical products. It also markets and distributes animal care products and offers distribution, warehousing and logistics support to pharmaceutical manufacturers and medical device suppliers. The company offers products under various brands such as Symbion, Pro Pharma, Minfosa, Master Pet, Vita Pet, Black Hawk and Faulding among others. EBOS serves private and public hospitals, general practitioners, aged care facilities, community centers, pharmacies, professionals, consumers, pet stores, veterinary clinics and manufacturers. It has operational presence in Australia and New Zealand. EBOS is headquartered in Docklands, Victoria, Australia.
EBOS Group Ltd (EBO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
EBOS Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
EBOS Group Ltd, Medical Devices Deals, 2012 to YTD 2018 9
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
EBOS Completes Private Placement Of Shares For USD 73 Million 11
EBOS Announces Rights Issue Of Shares For USD 121 Million 12
Acquisition 13
Ebos Group Receives Shareholders' Approval To Acquire Symbion From Zuellig Group For USD 886 Million 13
EBOS Group Ltd-Key Competitors 15
EBOS Group Ltd-Key Employees 16
EBOS Group Ltd-Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 19
Financial Announcements 19
Aug 23, 2018: EBOS delivers record 2018 earnings 19
Feb 21, 2018: EBOS delivers record first-half earnings 20
Aug 24, 2017: EBOS reports record earnings for 2017 22
Feb 22, 2017: EBOS Group Announces Strong first half delivers double-digit revenue and profit growth 24
Corporate Communications 26
Dec 13, 2017: EBOS Group announces its next CEO 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27
List Of Figure
List of Figures
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
EBOS Group Ltd, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
EBOS Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
EBOS Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
EBOS Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
EBOS Group Ltd, Medical Devices Deals, 2012 to YTD 2018 9
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
EBOS Completes Private Placement Of Shares For USD 73 Million 11
EBOS Announces Rights Issue Of Shares For USD 121 Million 12
Ebos Group Receives Shareholders' Approval To Acquire Symbion From Zuellig Group For USD 886 Million 13
EBOS Group Ltd, Key Competitors 15
EBOS Group Ltd, Key Employees 16
EBOS Group Ltd, Other Locations 17
EBOS Group Ltd, Subsidiaries 17
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
EBOS Group Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.